Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into
abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of
ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce
the level of prostate specific antigen (PSA) in PCa patients, and help to reduce tumors,
extending the lifespan of patients with advanced PCa for several years, and the toxicity is
acceptable.